News FDA decision on oral Wegovy coming in Q4 Novo Nordisk has had its NDA for an oral formulation of Wegovy accepted by the FDA. It would be the first obesity-targeted GLP-1 in pill form.
News Novo sues Lilly over 'misleading' GLP-1 ad campaigning The rivalry between Novo Nordisk and Eli Lilly in the GLP-1 market has spilled over into the courts in the US, with claims of misleading advertising.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
